dexamethasone
Pre-clinical- Indications
- Rheumatoid arthritis
Company intelligence / Profile preview
Chariton Pharmaceuticals
Chicago, Illinois, United Statescharitonpharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Chariton Pharmaceuticals develops novel drug candidates targeting rheumatoid arthritis and pain. The company’s lead program, CP‑001, appears to be in the early stages of development. No published clinical results are available yet. [1]
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Chariton Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chariton Pharmaceuticals.